CONMED Q3 sales $304.6M (+10.7% YoY); adj. EPS $0.90 (+16.9%); raises FY guidance

CONMED Corp

2023-Q3 EPS reported $0.99 revenue$917,699,000

Revenue of $304.6M, +10.7% reported (+11.9% constant currency). Domestic +9.5%, International +12.3%.
GAAP diluted EPS $0.50 (vs $1.48); Adjusted diluted EPS $0.90, up 16.9% from $0.77.
General Surgery sales $179.9M (+15% reported); Orthopedic Surgery $124.7M (+5.1%).
Full-year revenue guidance raised to $1.24B-$1.26B; adj. EPS guidance raised to $3.45-$3.55.
Adjusted EBITDA margin 19.6% vs 19.4% prior year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.5

CONMED Corp updated its the third quarter ended September 30, 2023 guidance (reaffirmed).

Period: the third quarter ended September 30, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On October 25, 2023, CONMED Corporation issued a press release announcing financial results for the third quarter ended September 30, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

CONMED Corp filing history →

Source: SEC EDGAR

accession 0001174947-23-001234

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.